Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: The Early Markers for Autism (EMA) study: A case-control study

Ousseny Zerbo, Cathleen Yoshida, Judith K. Grether, Judith A Van de Water, Paul Ashwood, Gerald N. Delorenze, Robin L Hansen, Marty Kharrazi, Lisa A. Croen

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Biologic markers of infection and inflammation have been associated with Autism Spectrum Disorders (ASD) but prior studies have largely relied on specimens taken after clinical diagnosis. Research on potential biologic markers early in neurodevelopment is required to evaluate possible causal pathways and screening profiles.Objective: To investigate levels of cytokines and chemokines in newborn blood specimens as possible early biologic markers for autism.Methods: We conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, California, USA. The study population included children ascertained from the California Department of Developmental Services with Autism Spectrum Disorder (ASD, n = 84), or developmental delay but not ASD (DD, n = 49), and general population controls randomly sampled from the birth certificate files and frequency matched to ASD cases on sex, birth month and birth year (GP, n = 159). Cytokine and chemokine concentrations were measured in archived neonatal blood specimens collected for routine newborn screening.Results: Cytokines were not detected in the vast majority of newborn samples regardless of case or control status. However, the chemokine monocyte chemotactic protein-1 (MCP-1) was elevated and the chemokine Regulated upon Activation Normal T-Cell Expressed and Secreted (RANTES) was decreased in ASD cases compared to GP controls. The chemokines macrophage inflammatory protein-1alpha (MIP-1α) and RANTES were decreased in children with DD compared to GP controls.Conclusion: Measurement of immune system function in the first few days of life may aid in the early identification of abnormal neurodevelopment and shed light on the biologic mechanisms underlying normal neurodevelopment.

Original languageEnglish (US)
Article number113
JournalJournal of Neuroinflammation
Volume11
DOIs
StatePublished - Jun 20 2014

Fingerprint

Autistic Disorder
Chemokines
Case-Control Studies
Cytokines
Biomarkers
Newborn Infant
Parturition
T-Lymphocytes
Birth Certificates
Macrophage Inflammatory Proteins
Population Control
Chemokine CCL2
Prenatal Diagnosis
Population
Autism Spectrum Disorder
Immune System
Inflammation
Infection
Research

Keywords

  • Autism spectrum disorders
  • Chemokines
  • Cytokines
  • Newborn

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Neurology
  • Immunology
  • Neuroscience(all)
  • Medicine(all)

Cite this

Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder : The Early Markers for Autism (EMA) study: A case-control study. / Zerbo, Ousseny; Yoshida, Cathleen; Grether, Judith K.; Van de Water, Judith A; Ashwood, Paul; Delorenze, Gerald N.; Hansen, Robin L; Kharrazi, Marty; Croen, Lisa A.

In: Journal of Neuroinflammation, Vol. 11, 113, 20.06.2014.

Research output: Contribution to journalArticle

@article{4f46d87f6af74a3e8c017f9da1e5c8ba,
title = "Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: The Early Markers for Autism (EMA) study: A case-control study",
abstract = "Background: Biologic markers of infection and inflammation have been associated with Autism Spectrum Disorders (ASD) but prior studies have largely relied on specimens taken after clinical diagnosis. Research on potential biologic markers early in neurodevelopment is required to evaluate possible causal pathways and screening profiles.Objective: To investigate levels of cytokines and chemokines in newborn blood specimens as possible early biologic markers for autism.Methods: We conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, California, USA. The study population included children ascertained from the California Department of Developmental Services with Autism Spectrum Disorder (ASD, n = 84), or developmental delay but not ASD (DD, n = 49), and general population controls randomly sampled from the birth certificate files and frequency matched to ASD cases on sex, birth month and birth year (GP, n = 159). Cytokine and chemokine concentrations were measured in archived neonatal blood specimens collected for routine newborn screening.Results: Cytokines were not detected in the vast majority of newborn samples regardless of case or control status. However, the chemokine monocyte chemotactic protein-1 (MCP-1) was elevated and the chemokine Regulated upon Activation Normal T-Cell Expressed and Secreted (RANTES) was decreased in ASD cases compared to GP controls. The chemokines macrophage inflammatory protein-1alpha (MIP-1α) and RANTES were decreased in children with DD compared to GP controls.Conclusion: Measurement of immune system function in the first few days of life may aid in the early identification of abnormal neurodevelopment and shed light on the biologic mechanisms underlying normal neurodevelopment.",
keywords = "Autism spectrum disorders, Chemokines, Cytokines, Newborn",
author = "Ousseny Zerbo and Cathleen Yoshida and Grether, {Judith K.} and {Van de Water}, {Judith A} and Paul Ashwood and Delorenze, {Gerald N.} and Hansen, {Robin L} and Marty Kharrazi and Croen, {Lisa A.}",
year = "2014",
month = "6",
day = "20",
doi = "10.1186/1742-2094-11-113",
language = "English (US)",
volume = "11",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder

T2 - The Early Markers for Autism (EMA) study: A case-control study

AU - Zerbo, Ousseny

AU - Yoshida, Cathleen

AU - Grether, Judith K.

AU - Van de Water, Judith A

AU - Ashwood, Paul

AU - Delorenze, Gerald N.

AU - Hansen, Robin L

AU - Kharrazi, Marty

AU - Croen, Lisa A.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - Background: Biologic markers of infection and inflammation have been associated with Autism Spectrum Disorders (ASD) but prior studies have largely relied on specimens taken after clinical diagnosis. Research on potential biologic markers early in neurodevelopment is required to evaluate possible causal pathways and screening profiles.Objective: To investigate levels of cytokines and chemokines in newborn blood specimens as possible early biologic markers for autism.Methods: We conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, California, USA. The study population included children ascertained from the California Department of Developmental Services with Autism Spectrum Disorder (ASD, n = 84), or developmental delay but not ASD (DD, n = 49), and general population controls randomly sampled from the birth certificate files and frequency matched to ASD cases on sex, birth month and birth year (GP, n = 159). Cytokine and chemokine concentrations were measured in archived neonatal blood specimens collected for routine newborn screening.Results: Cytokines were not detected in the vast majority of newborn samples regardless of case or control status. However, the chemokine monocyte chemotactic protein-1 (MCP-1) was elevated and the chemokine Regulated upon Activation Normal T-Cell Expressed and Secreted (RANTES) was decreased in ASD cases compared to GP controls. The chemokines macrophage inflammatory protein-1alpha (MIP-1α) and RANTES were decreased in children with DD compared to GP controls.Conclusion: Measurement of immune system function in the first few days of life may aid in the early identification of abnormal neurodevelopment and shed light on the biologic mechanisms underlying normal neurodevelopment.

AB - Background: Biologic markers of infection and inflammation have been associated with Autism Spectrum Disorders (ASD) but prior studies have largely relied on specimens taken after clinical diagnosis. Research on potential biologic markers early in neurodevelopment is required to evaluate possible causal pathways and screening profiles.Objective: To investigate levels of cytokines and chemokines in newborn blood specimens as possible early biologic markers for autism.Methods: We conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, California, USA. The study population included children ascertained from the California Department of Developmental Services with Autism Spectrum Disorder (ASD, n = 84), or developmental delay but not ASD (DD, n = 49), and general population controls randomly sampled from the birth certificate files and frequency matched to ASD cases on sex, birth month and birth year (GP, n = 159). Cytokine and chemokine concentrations were measured in archived neonatal blood specimens collected for routine newborn screening.Results: Cytokines were not detected in the vast majority of newborn samples regardless of case or control status. However, the chemokine monocyte chemotactic protein-1 (MCP-1) was elevated and the chemokine Regulated upon Activation Normal T-Cell Expressed and Secreted (RANTES) was decreased in ASD cases compared to GP controls. The chemokines macrophage inflammatory protein-1alpha (MIP-1α) and RANTES were decreased in children with DD compared to GP controls.Conclusion: Measurement of immune system function in the first few days of life may aid in the early identification of abnormal neurodevelopment and shed light on the biologic mechanisms underlying normal neurodevelopment.

KW - Autism spectrum disorders

KW - Chemokines

KW - Cytokines

KW - Newborn

UR - http://www.scopus.com/inward/record.url?scp=84902741281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902741281&partnerID=8YFLogxK

U2 - 10.1186/1742-2094-11-113

DO - 10.1186/1742-2094-11-113

M3 - Article

C2 - 24951035

AN - SCOPUS:84902741281

VL - 11

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

M1 - 113

ER -